Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis | International Journal of Technology Assessment in Health Care | Cambridge Core (original) (raw)

Abstract

Objectives: The aim of this study was to assess the test performance and clinical effectiveness of photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in people suspected of new or recurrent bladder cancer.

Methods: A systematic review was conducted of randomized controlled trials (RCTs), nonrandomized comparative studies, or diagnostic cross-sectional studies comparing PDD with WLC. Fifteen electronic databases and Web sites were searched (last searches April 2008). For clinical effectiveness, only RCTs were considered.

Results: Twenty-seven studies (2,949 participants) assessed test performance. PDD had higher sensitivity than WLC (92 percent, 95 percent confidence interval [CI], 80–100 percent versus 71 percent, 95 percent CI, 49–93 percent) but lower specificity (57 percent, 95 percent CI, 36–79 percent versus 72 percent, 95 percent CI, 47–96 percent). For detecting higher risk tumors, median range sensitivity of PDD (89 percent [6–100 percent]) was higher than WLC (56 percent [0–100 percent]) whereas for lower risk tumors it was broadly similar (92 percent [20–95 percent] versus 95 percent [8–100 percent]). Four RCTs (709 participants) using 5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical effectiveness. Using PDD at transurethral resection of bladder tumor (TURBT) resulted in fewer residual tumors at check cystoscopy (relative risk [RR], 0.37, 95 percent CI, 0.20–0.69) and longer recurrence-free survival (RR, 1.37, 95 percent CI, 1.18–1.59), compared with WLC.

Conclusions: PDD detects more bladder tumors than WLC, including more high-risk tumors. Based on four RCTs reporting clinical effectiveness, 5-aminolaevulinic acid–mediated PDD at TURBT facilitates a more complete resection and prolongs recurrence-free survival.

References

  1. Babjuk, M, Soukup, V, Petrik, R, Jirsa, M, Dvoracek, J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96:798–802.CrossRefGoogle ScholarPubMed

  2. Hendricksen, K, Moonen, PM, der Heijden, AG, Witjes, JA. False-positive lesions detected by fluorescence cystoscopy: Any association with p53 and p16 expression? World J Urol. 2006;24:597–601.CrossRefGoogle ScholarPubMed

  3. Jichlinski, P, Wagnieres, G, Forrer, M, et al. Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer. Urol Res. 1997;25:S3–S6.CrossRefGoogle Scholar

  4. Kausch, I, Sommerauer, M, Montorsi, F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: A systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57:595–606.CrossRefGoogle ScholarPubMed

  5. Koenig, F, McGovern, FJ, Larne, R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999;83:129–135.CrossRefGoogle ScholarPubMed

  6. Kriegmair, M, Zaak, D, Rothenberger, KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002;168:475–478.CrossRefGoogle ScholarPubMed

  7. Leeflang, MM, Deeks, JJ, Gatsonis, C, Bossuyt, PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–897.Google Scholar

  8. Macaskill, P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol. 2004;57:925–932.CrossRefGoogle Scholar

  9. Masters, JRW, Popert, RJM, Thompson, PM, et al. Intravesical chemotherapy with epirubicin: A dose response study. J Urol. 1999;161:1490–1493.CrossRefGoogle ScholarPubMed

  10. Mowatt, G, Zhu, S, Kilonzo, M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14:1–331, iii–iv.CrossRefGoogle ScholarPubMed

  11. Sangar, VK, Ragavan, N, Matanhelia, SS, Watson, MW, Blades, RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005;95:59–63.CrossRefGoogle ScholarPubMed

  12. Stenzl, AS, Roessler, WR, Fradet, YF, et al. HEXVIX fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: A multicentre prospective randomized trial. Abstract 1010. Eur Urol Suppl. 2009;8:373.CrossRefGoogle Scholar

  13. Sylvester, RJ, Oosterlinck, W. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Has the evidence changed? Eur Urol. 2009;56:43–45.CrossRefGoogle ScholarPubMed

  14. Sylvester, RJ, Oosterlinck, W, Van Der Meijden, APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–2190.CrossRefGoogle ScholarPubMed

  15. Whiting, P, Rutjes, AW, Reitsma, JB, Bossuyt, PM, Kleijnen, J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.CrossRefGoogle ScholarPubMed

  16. Zaak, D, Karl, A, Knuchel, R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005;96:217–222.CrossRefGoogle ScholarPubMed